Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

14.22 +0.06 (+0.42%)

Streaming Delayed Price Updated: 2:16 PM EDT, Sep 2, 2026 Add to My Watchlist

Price and Volume

Volume	1,637,376
Open	14.15
Bid (Size)	14.21 (500)
Ask (Size)	14.23 (300)
Prev. Close	14.16
Today's Range	14.06 - 14.72
52wk Range	12.07 - 29.23
Shares Outstanding	97,381,774
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 26, 2026

Gainers Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.0 million. Summit Therapeutics...

Via Benzinga

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China

August 25, 2026

From Summit Therapeutics

Via Business Wire

Performance

YTD	-18.8%	-18.8%
1 Month	+9.0%	+9.0%
3 Month	-4.3%	-4.3%
6 Month	-5.9%	-5.9%
1 Year	-40.4%	-40.4%

More News

Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology

August 25, 2026

From Summit Therapeutics

Via Business Wire

GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity ↗

August 24, 2026

Via The Motley Fool

Summit Therapeutics (SMMT) Reports In-Line Q2 Loss; Stock Eases Amid Pivotal PDUFA Catalyst ↗

July 23, 2026

Via Chartmill

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

August 12, 2026

From Summit Therapeutics

Via Business Wire

Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty

August 06, 2026

From Lowey Dannenberg, P.C.

Via GlobeNewswire

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer

August 05, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Q2 Earnings Call Highlights ↗

July 23, 2026

Via MarketBeat

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

July 23, 2026

From Summit Therapeutics

Via Business Wire

Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

July 22, 2026

From Summit Therapeutics

Via Business Wire

Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study

July 22, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026

July 16, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.

July 14, 2026

From Summit Therapeutics

Via Business Wire

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 30, 2026

Via The Motley Fool

Summit Therapeutics Announces Proposed Public Offering of Common Stock

June 09, 2026

From Summit Therapeutics

Via Business Wire

Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference

June 04, 2026

From Summit Therapeutics

Via Business Wire

This Emerging Risk Is Unlike Anything the Biotech Industry Has Ever Experienced ↗

May 31, 2026

Via The Motley Fool

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

May 31, 2026

From Summit Therapeutics

Via Business Wire

Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026

May 30, 2026

From Summit Therapeutics

Via Business Wire

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗

May 23, 2026

Via The Motley Fool

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗

May 23, 2026

Via The Motley Fool

A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology

May 14, 2026

From USA News Group

Via GlobeNewswire

What's going on in today's session ↗

May 01, 2026

Via Chartmill

Which stocks are moving on Friday? ↗

May 01, 2026

Via Chartmill

Frequently Asked Questions

Is Summit Therapeutics Inc. - Common Stock publicly traded?

Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.

What exchange does Summit Therapeutics Inc. - Common Stock trade on?

Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?

The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market

What is the current price of Summit Therapeutics Inc. - Common Stock?

The current price of Summit Therapeutics Inc. - Common Stock is 14.22

When was Summit Therapeutics Inc. - Common Stock last traded?

The last trade of Summit Therapeutics Inc. - Common Stock was at 09/02/26 02:16 PM ET

What is the market capitalization of Summit Therapeutics Inc. - Common Stock?

The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.38B

How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?

Summit Therapeutics Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.